Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{ga

Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{ga

Item

http://www.wikidata.org/entity/Q37275103

Q37275103

about

Studies of retroviral infection in humanized mice Recent developments in human immunodeficiency virus-1 latency research New generation humanized mice for virus research: comparative aspects and future prospects A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1 Therapy for persistent HIV.Eradication therapies for HIV Infection: time to begin again.Animal models for HIV/AIDS research Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model Humanized Rag1-/- γc-/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis Influence of age, irradiation and humanization on NSG mouse phenotypes.In vivo platforms for analysis of HIV persistence and eradication.A Simple Mouse Model for the Study of Human Immunodeficiency Virus.HIV-1 cellular and tissue replication patterns in infected humanized mice.Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year.Pharmacologic opportunities for HIV prevention.IL-2 receptor γ-chain molecule is critical for intestinal T-cell reconstitution in humanized mice.HIV-1 transcription and latency: an update.Humanized mouse models of HIV infection Humanized mice for immune system investigation: progress, promise and challenges Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.Curing HIV: Pharmacologic approaches to target HIV-1 latency.HIV-1 immunopathogenesis in humanized mouse models.The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models.Latest animal models for anti-HIV drug discovery.Lack of Trex1 Causes Systemic Autoimmunity despite the Presence of Antiretroviral Drugs.TALEN gene editing takes aim on HIV.In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy.

P2860

Q26849806-46D364DD-E191-437E-8DEB-BFA0CA755BFF Q27013114-B21B9CF7-ECB1-4B8D-87C9-4375ABE1066F Q27014786-EE34A2A1-18F4-4661-88F7-277EA810CB58 Q28478394-86FFCDD3-3BC3-4272-9F91-A89683F5DDA0 Q28728527-5F765702-2B74-4793-91BD-906C1C704A76 Q30386370-45437B98-7661-40D2-BFA1-F1883D617DC4 Q30399588-DD73EADA-CBA5-49CB-9A32-15AF22187687 Q30423656-FC4AAD20-9EFD-444F-9BE1-A8ECE8A12975 Q33625213-97A69BCA-3479-497C-AD69-F1DD8B23D758 Q33676640-62C75B16-67F8-4598-85A0-F11242F308C8 Q33939330-AD49ED41-3133-4B14-9BD5-5CD7FB5EAD18 Q34100221-388AC1B6-784A-4E02-9C7C-5071E3F8A2CE Q34474320-B0151791-BCB8-4B28-9F8E-3149EFDCE514 Q35206268-D0AF82BC-78AA-4DF7-9FBE-4E531F3DDDC9 Q35665924-94507909-49F2-4029-8C96-D248414D9A7F Q35794988-88A2A6BA-02E0-4581-A4DC-F483F6588511 Q35826239-5F080010-70CF-4AD6-AE73-D358E7FFD808 Q35921136-040BE591-F1B8-4B40-9302-5BC2E5845C64 Q36175327-862CD2EF-D107-43DD-8596-CB59E103EF5F Q36515119-29EFB586-F321-4190-896C-F885FDE86670 Q36601933-FEE67B14-0C29-4917-AF74-68A3AE17671F Q36709101-4379F2F4-7504-46FC-87AE-0865A03250BE Q36756422-79C76652-41A2-4B1A-BCD9-50B092FD2A49 Q36905431-E4F96438-46F8-4873-954A-F97D4C15F1F5 Q36972070-CDB8025D-C7BA-468D-B4A3-C08053A2BA5A Q36976156-42DCBA00-EAF1-475F-8667-46BD57210D0B Q37089865-139749EF-2D9F-4626-9506-ED2EA73EE886 Q37111994-2164FAE2-607D-4960-B492-94174BA4A712 Q37195155-116D2F78-A49A-43B5-9CE8-135B96B22059 Q37236504-B7871D10-A554-4B27-8C13-4FBF78D3189B Q37258271-7E3337AC-5CDB-4FD7-BC6A-B522A4CA30D8 Q37259407-1EEB7963-87DE-4237-8E7D-CA34330AE235 Q37645582-D998E78F-2251-444A-9099-5818633A3178 Q37676228-ECBE91DB-E130-4700-8E90-E9EB748DC55F Q37900419-D4BBD817-BC75-4E61-8507-30C92A82B32D Q38263295-9BE0EF60-C4FB-4CF1-B1F3-3CBE240C5FB8 Q38611198-5664BF9A-E487-42AB-BCF7-77DC6F4C52E4 Q38832507-AE61ED17-293E-433A-9029-1B21D9BC2F51 Q39315707-24D95EE2-7961-4382-9AF1-866FCAB62D4D Q39547654-321DF932-2D40-45EF-BEDB-5DEA0C0EF593

P2860

Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{ga

Item

http://www.wikidata.org/entity/Q37275103

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs